Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 10/31/2017) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
86145900 |
LAW OFFICE ASSIGNED |
LAW OFFICE 112 |
MARK SECTION |
MARK |
BEFINRA |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
BEFINRA |
OWNER SECTION |
NAME |
Eli Lilly and Company |
STREET |
Lilly Corporate Center |
CITY |
Indianapolis |
STATE |
Indiana |
ZIP/POSTAL CODE |
46285 |
COUNTRY |
United States |
PHONE |
317 651 1346 |
FAX |
317 276 1919 |
EMAIL |
XXXX |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders,
atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders,
cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal
diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases
and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, sleep disorders, urological disorders;
antidepressants; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases |
GOODS OR SERVICES DELETED FROM THE APPLICATION |
alcohol use disorders, |
GOODS OR SERVICES FOR WHICH APPLICANT HAS A CONTINUED BONA FIDE INTENTION, AND IS ENTITLED, TO USE |
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's, anxiety disorders, atherosclerosis,
autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders,
cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders,
inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders,
neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, sleep disorders, urological disorders; antidepressants; Diagnostic
agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases |
EXTENSION SECTION |
EXTENSION NUMBER |
4 |
ONGOING EFFORT |
product or service research or development |
ALLOWANCE MAIL DATE |
07/22/2014 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
150 |
TOTAL AMOUNT |
150 |
SIGNATURE SECTION |
SIGNATURE |
/reljr44/ |
SIGNATORY'S NAME |
Robert E. Lee |
SIGNATORY'S POSITION |
Assistant General Patent Counsel |
DATE SIGNED |
06/27/2016 |
SIGNATORY'S PHONE NUMBER |
317-276-9624 |
FILING INFORMATION |
SUBMIT DATE |
Tue Jun 28 08:12:08 EDT 2016 |
TEAS STAMP |
USPTO/ESU-XX.X.XX.XX-2016
0628081208256226-86145900
-55090b1758172c855b799201
269d0a26d868680c4a5c7ba82
1f1077f6fa309968-DA-10246
-20160627120808137198 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 10/31/2017) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: BEFINRA
SERIAL NUMBER: 86145900
The applicant, Eli Lilly and Company, having an address of
Lilly Corporate Center
Indianapolis, Indiana 46285
United States
317 651 1346
317 276 1919
XXXX (not authorized)
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 07/22/2014.
For International Class 005:
Current identification: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune
diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic
fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders,
inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders,
neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, sleep disorders, urological disorders; antidepressants; Diagnostic
agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases
This filing does
NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified for this specific class; these goods/services are
permanently deleted from this application: alcohol use disorders,
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood
disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological
diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and
disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders,
neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, sleep disorders, urological disorders; antidepressants; Diagnostic agents and substances for medical purposes;
radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative amyloid diseases
This is the fourth extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: product or service research or development
A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /reljr44/ Date Signed: 06/27/2016
Signatory's Name: Robert E. Lee
Signatory's Position: Assistant General Patent Counsel
Signatory's Phone: 317-276-9624
RAM Sale Number: 86145900
RAM Accounting Date: 06/28/2016
Serial Number: 86145900
Internet Transmission Date: Tue Jun 28 08:12:08 EDT 2016
TEAS Stamp: USPTO/ESU-XX.X.XX.XX-2016062808120825622
6-86145900-55090b1758172c855b799201269d0
a26d868680c4a5c7ba821f1077f6fa309968-DA-
10246-20160627120808137198